Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Henri Becquerel
About this trial
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.
Eligibility criteria
Qualifiers
Patient over 18 years of age,
Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to the recommendations of the WHO 2016 classification of hematological malignancies,
All stages (I-IV)
All IPI scores (0-5)
Disqualifiers
Patient who has already started chemotherapy treatment,
Contraindication to FDG PET-CT,
No mediastinal involvement,
Positive HIV serology,
Trial design
Treatments tested in this trial
- Circulating tumor DNA monitoring
Treatment groups
87 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov